These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

708 related items for PubMed ID: 10687982

  • 1. Prostate cancer detection at low prostate specific antigen.
    Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R.
    J Urol; 2000 Mar; 163(3):806-12. PubMed ID: 10687982
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
    Schröder FH, van der Maas P, Beemsterboer P, Kruger AB, Hoedemaeker R, Rietbergen J, Kranse R.
    J Natl Cancer Inst; 1998 Dec 02; 90(23):1817-23. PubMed ID: 9839522
    [Abstract] [Full Text] [Related]

  • 3. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A.
    J Urol; 2001 Oct 02; 166(4):1339-42. PubMed ID: 11547069
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG, Pinover WH, Horwitz EM, Parlanti A, Mazzoni S, Raysor S, Mirchandani I, Greenberg RE, Pollack A, Hanks GE, Watkins-Bruner D.
    Urology; 2003 Apr 02; 61(4):754-9. PubMed ID: 12670560
    [Abstract] [Full Text] [Related]

  • 6. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
    Presti JC, Hovey R, Carroll PR, Shinohara K.
    J Urol; 1996 Nov 02; 156(5):1685-90. PubMed ID: 8863571
    [Abstract] [Full Text] [Related]

  • 7. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
    Schröder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R.
    Urology; 2001 Jan 02; 57(1):83-90. PubMed ID: 11164149
    [Abstract] [Full Text] [Related]

  • 8. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.
    Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC.
    J Urol; 1994 May 02; 151(5):1283-90. PubMed ID: 7512659
    [Abstract] [Full Text] [Related]

  • 9. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen.
    Lodding P, Aus G, Bergdahl S, Frösing R, Lilja H, Pihl CG, Hugosson J.
    J Urol; 1998 Mar 02; 159(3):899-903. PubMed ID: 9474178
    [Abstract] [Full Text] [Related]

  • 10. Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mL.
    Kim HS, Jeon SS, Choi JD, Kim W, Han DH, Jeong BC, Seo SI, Lee KS, Lee SW, Lee HM, Choi HY.
    Urology; 2010 Oct 02; 76(4):919-22. PubMed ID: 20303152
    [Abstract] [Full Text] [Related]

  • 11. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ, Kranse R, de Koning HJ, Schröder FH.
    Urology; 2004 Feb 02; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [Abstract] [Full Text] [Related]

  • 12. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A, Dworschack RT, Partin AW.
    J Urol; 2002 Aug 02; 168(2):504-8. PubMed ID: 12131298
    [Abstract] [Full Text] [Related]

  • 13. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.
    Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, Kavoussi LR, MacFarlane MT, Southwick PC.
    J Urol; 1994 Dec 02; 152(6 Pt 1):2031-6. PubMed ID: 7525994
    [Abstract] [Full Text] [Related]

  • 14. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff.
    Luboldt HJ, Bex A, Swoboda A, Hüsing J, Rübben H, Early Detection Project Group of the German Urological Association.
    Eur Urol; 2001 Feb 02; 39(2):131-7. PubMed ID: 11223671
    [Abstract] [Full Text] [Related]

  • 15. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
    Bangma CH, Kranse R, Blijenberg BG, Schröder FH.
    Urology; 1995 Dec 02; 46(6):779-84. PubMed ID: 7502415
    [Abstract] [Full Text] [Related]

  • 16. The risks of prostate cancer detection by transrectal ultrasound guide biopsy in Thai men with abnormal prostatic-specific antigen or abnormal digital rectal examination.
    Leewansangtong S, Tantiwong A, Ratanarapee S, Nualyong C, Soontrapa S.
    J Med Assoc Thai; 2000 Dec 02; 83(12):1519-24. PubMed ID: 11253893
    [Abstract] [Full Text] [Related]

  • 17. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
    Recker F, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R.
    J Urol; 2001 Sep 02; 166(3):851-5. PubMed ID: 11490232
    [Abstract] [Full Text] [Related]

  • 18. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.
    Roobol MJ, Steyerberg EW, Kranse R, Wolters T, van den Bergh RC, Bangma CH, Schröder FH.
    Eur Urol; 2010 Jan 02; 57(1):79-85. PubMed ID: 19733959
    [Abstract] [Full Text] [Related]

  • 19. [Diagnostic algorithm based on a multivariate model to reduce the percentage of negative prostatic biopsies in patients with changed PSA or suspicious rectal palpation].
    Valer Algarabel J, Agüera Fernández L, Adot Zurbano JM, Virseda Chamorro M, Marcos Díez J, Gómez López A, Alpuente Román C.
    Actas Urol Esp; 2000 Jan 02; 24(7):549-59. PubMed ID: 11011445
    [Abstract] [Full Text] [Related]

  • 20. [Early diagnosis of prostate carcinoma with reference to the density of prostate-specific antigen].
    Schmid HP, Ravery V, Toublanc M, Boccon-Gibod L.
    Schweiz Med Wochenschr; 1996 Sep 07; 126(36):1530-5. PubMed ID: 8927956
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.